Page last updated: 2024-12-06

beclobrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Beclobrate is a synthetic compound that functions as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. PPARα is a nuclear receptor involved in the regulation of lipid metabolism, inflammation, and cell proliferation. Beclobrate has been studied for its potential therapeutic effects in various conditions, including hyperlipidemia, diabetes, and cancer. Its mechanism of action involves binding to PPARα, which activates downstream signaling pathways leading to the regulation of gene expression. Beclobrate has demonstrated lipid-lowering effects by reducing triglyceride and cholesterol levels. Additionally, it exhibits anti-inflammatory properties and may have protective effects against oxidative stress. However, the clinical development of beclobrate has been limited due to potential side effects such as hepatotoxicity. Despite this, its pharmacological profile and PPARα agonism make it a promising molecule for further investigation in the context of metabolic diseases and other conditions.'

beclobrate: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51348
CHEMBL ID152684
CHEBI ID135463
SCHEMBL ID49779
MeSH IDM0075365

Synonyms (41)

Synonym
beclobrate
sgd-24774
beclosclerin
ethyl 2-(4-((4-chlorophenyl)methyl)phenoxy)-2-methylbutanoate
beclobrato [inn-spanish]
butanoic acid, 2-(4-((4-chlorophenyl)methyl)phenoxy)-2-methyl-, ethyl ester, (+-)-
(+-)-ethyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methylbutyrate
einecs 259-912-4
beclobrato [spanish]
beclobratum [inn-latin]
ethyl (+-)-2-((alpha-(p-chlorophenyl)-p-tolyl)oxy)-2-methylbutyrate
sgd 24774
(+-)-2-(4-((4'-chlorphenyl)methyl)-phenoxy)-2-methylbutansaure-ethylester [german]
butyric acid, 2-(4-(4-chlorobenzyl)phenoxy)-2-methyl-, ethyl ester, (+-)-
(+-)-2-(4-(4-chlorobenzyl)phenoxy)-2-methylbutyric acid ethyl ester
sgd 247-74
CHEBI:135463
CHEMBL152684
ethyl 2-[4-[(4-chlorophenyl)methyl]phenoxy]-2-methylbutanoate
c20h23clo3
AKOS016014264
unii-usz5my269r
(+-)-2-(4-((4'-chlorphenyl)methyl)-phenoxy)-2-methylbutansaure-ethylester
beclobrate [inn:ban]
usz5my269r ,
beclobratum
beclobrato
55937-99-0
beclobrate [mi]
ethyl (+/-)-2-((.alpha.-(p-chlorophenyl)-p-tolyl)oxy)-2-methylbutyrate
beclobrate [who-dd]
beclobrate [inn]
beclobrate [mart.]
SCHEMBL49779
ethyl 2-(4-(4-chlorobenzyl)phenoxy)-2-methylbutanoate
FT-0702379
Q27291259
HY-15387
DTXSID101021600
ethyl 2-{4-[(4-chlorophenyl)methyl]phenoxy}-2-methylbutanoate
DTXSID00866522

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Application of the assay in a pilot pharmacokinetic study showed significant differences between the kinetics of the two enantiomers."( Pharmacokinetic studies with the lipid-regulating agent beclobrate: enantiospecific assay for beclobric acid using a new fluorescent chiral coupling component (S-FLOPA).
Mayer, S; Mutschler, E; Spahn-Langguth, H, 1991
)
0.53
" Pharmacodynamic and pharmacokinetic investigations suggest that once-daily administration in a dosage of 100 mg is admissible."( Beclobrate:pharmacodynamic properties and therapeutic use in hyperlipidemia.
Hörl, WH; Schollmeyer, P; Wanner, C; Wieland, H, 1991
)
1.72
" For clinical application a dose regimen of once daily is indicated by the pharmacokinetic results."( [Pharmacokinetics and bioequivalence of two peroral beclobrate preparations].
Gikalov, I; Ifflaender, U, 1987
)
0.52
" Pharmacokinetic data were only available for the total concentration, but not for the two enantiomers."( Pharmacokinetics of beclobric acid enantiomers and their conjugates after single and multiple oral dosage of racemic beclobrate.
Gikalov, I; Mayer, S; Mutschler, E; Spahn-Langguth, H, 1993
)
0.5

Dosage Studied

Beclobrate was given in a dosage of 100 mg twice daily and eniclobrate in a dose of 130mg twice daily.

ExcerptRelevanceReference
" Pharmacodynamic and pharmacokinetic investigations suggest that once-daily administration in a dosage of 100 mg is admissible."( Beclobrate:pharmacodynamic properties and therapeutic use in hyperlipidemia.
Hörl, WH; Schollmeyer, P; Wanner, C; Wieland, H, 1991
)
1.72
" Beclobrate was given in a dosage of 100 mg twice daily and eniclobrate in a dosage of 130 mg twice daily."( Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II b.
Irsigler, K; Lageder, H; Najemnik, C; Regal, H, 1981
)
1.42
" Multiple dosing increased irreversible binding 3- to 4-fold."( In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers.
Benet, LZ; Mayer, S; Mutschler, E; Sphahn-Langguth, H, 1993
)
0.29
" after repetitive dosage of 100 mg beclobrate once daily for 8 days."( Pharmacokinetics of beclobric acid enantiomers and their conjugates after single and multiple oral dosage of racemic beclobrate.
Gikalov, I; Mayer, S; Mutschler, E; Spahn-Langguth, H, 1993
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (43.48)18.7374
1990's12 (52.17)18.2507
2000's0 (0.00)29.6817
2010's1 (4.35)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.93 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (25.00%)5.53%
Reviews2 (8.33%)6.00%
Case Studies2 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other14 (58.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]